

Supplementary Material

Risk Factors for Severe COVID-19

Patients were identified as at risk for severe COVID-19 if they had one or more of the following risk factors as defined by Centers for Disease Control¹⁵: asthma, cancer, cerebrovascular disease, chronic kidney disease, chronic lung diseases, cystic fibrosis, diabetes, disabilities, heart conditions, human immunodeficiency virus (HIV), mental health conditions, dementia, overweight/obese, recent pregnancy, primary immunodeficiencies, smoking (former or current), had an organ or blood stem cell transplant, tuberculosis, use of corticosteroids or other immunosuppressants, and sickle cell disease. Some risk factors required additional rules. For cancer, we excluded basal cell carcinomas. For disabilities, we included autism, Down's syndrome, Attention-Deficit/Hyperactivity Disorder, developmental disorder (birth defects, intellectual and developmental disabilities, and learning disabilities), spinal cord injuries (hemiplegia, paraplegia, and quadriplegia), and cerebral palsy. For chronic kidney disease, we included stages 1-3 not requiring dialysis. For recent pregnancy, we identified all pregnancy-related visits within six weeks prior to index.

Covariates

We included the following baseline covariates in our propensity model: (i) patient demographics (sex, age at index, race/ethnicity), (ii) risk factors for severe COVID-19 described above (iii) previous exclusion criteria with extended lookback before index date, (iv) potential confounders including history of hypertension, liver disease (mild to severe), Chronic Kidney Disease (CKD) (all stages), psychosis, rheumatologic disease, thalassemia, number of healthcare visits before and up to index, most recent BMI, and (v) area-level statistics measured as proportion of

population for the following: ethnic groups, poverty status, unemployment status, and education (i.e., having a bachelor's degree, or a graduate or professional degree). BMI was binned into CDC categories with an additional level for missing²⁷.

Estimating projected number of preventable hospitalizations and deaths

To estimate projections of prevented hospitalizations and deaths with increases in uptake (based on the estimated effectiveness of Paxlovid from our analysis), we first calculated the current rate of each outcome event (hospitalization or death) as below:

$$\text{Current Event Rate} = \frac{\text{Cumulative events}}{N_{\text{Adjusted COVID-19 cases}}}$$

The number of cumulative COVID-19-related hospitalizations or deaths between December 2021 and February 2023 was obtained from published statistics²¹. The number of Adjusted COVID-19 cases in the above formula was calculated below by first splitting the total number of actual (cumulative) COVID-19 cases into Paxlovid takers and Non-takers as below, with eligibility set at 50% (0.5) at current uptake rate at 9% (0.09), and then multiplying the sum by the RR estimate for the event of interest (hospitalization or death) estimated from our outcome analysis, as shown below:

$$N_{\text{Paxlovid takers}} = N_{\text{cases}} \times \text{eligibility} \times \text{current uptake rate}$$

$$N_{\text{Non-takers}} = N_{\text{cases}} - N_{\text{Paxlovid takers}}$$

$$N_{\text{Adjusted COVID-19 cases}} = RR \times (N_{\text{Paxlovid takers}} + N_{\text{Non takers}})$$

We then used the Current Event Rate (hospitalization or death) to estimate new total numbers of hospitalized or deceased Paxlovid takers and Non-takers at a modified uptake rate of 50% (0.5) as follows:

$$N_{New\ Paxlovid\ takers} = N_{cases} \times eligibility \times modified\ uptake\ rate \times Current\ Event\ Rate \times RR$$

$$N_{New\ Non-takers} = (N_{cases} - N_{New\ Paxlovid\ takers}) \times Current\ Event\ Rate$$

$$N_{New\ Total\ Events} = N_{Paxlovid\ takers} + N_{Non\ takers}$$

We then obtained the percentage change in the number of events from the current to the modified level of uptake as below:

$$\% \text{ Change in Events} = \frac{N_{Cumulative\ events} - N_{New\ Total\ events}}{N_{Cumulative\ events}}$$

Finally, the percent change was multiplied by the cumulative hospitalizations or death counts to obtain the projected number of hospitalizations/deaths at the modified uptake level. To display these results visually, we systematically varied the uptake level between 0 to 100% and plotted the percent reduction in hospitalizations and deaths at three levels of eligibility: 30%, 50% and 70%, and these results are displayed in eFigure 3.

Weighting Approach

We obtained the estimated probabilities of Paxlovid exposure from the propensity model predicting exposure (ρ) to generate the weights to balance treatment groups on pretreatment baseline covariates prior to the analysis. Specifically, we used the weighting by the odds method¹⁷, which involves assigning a weight of 1 to treated patients, and a weight of $\rho / (1 - \rho)$ (i.e., the odds of treatment receipt) to untreated patients, enabling estimation of the Average Treatment effect in the Treated (ATT), or the average causal effect of Paxlovid on each outcome that would have been seen if everyone in the treated group received Paxlovid compared to if

none in the treated group received Paxlovid. We multiplied the weights in each treatment group by the proportion of patients in each corresponding group to generate stabilized weights¹⁸.

Balance on pretreatment covariates was assessed using absolute standardized mean differences (SMDs). SMDs were calculated by taking the difference in the weighted means, and dividing by the pooled weighted standard deviation across the treated and untreated groups.

The pooled standard deviation was calculated as below:

$$Pooled\ SD = \sqrt{\frac{(SD_{Treatment}^2 + SD_{Control}^2)}{2}}$$

List of Sensitivity Analyses

1. Sensitivity analysis including age ≥ 50 years as a risk factor for severe COVID-19
2. Sensitivity analysis including age ≥ 65 years as a risk factor for severe COVID-19
3. Sensitivity analysis excluding patients who died within 3 days of COVID-19 index date from eligible cohort
4. Sensitivity analysis dropping requirement of mild COVID-19 from eligibility definition
5. Sensitivity analysis dropping area level statistics from propensity model
6. Sensitivity analysis using a 90-day lookback for contraindicated medications and medical conditions for determining exclusions from eligible cohort
7. Sensitivity analysis dropping BMI as a predictor from the propensity model
8. Sensitivity analysis excluding patients receiving Paxlovid more than two days after index date from the treatment group

eTable 1. Concept Sets and OMOP Concept Names and IDs for Paxlovid Exposure

Concept set	concept	OMOP concept id
paxlovid	PAXLOVID - nirmatrelvir and ritonavir kit	36902202
	nirmatrelvir 150 MG Oral Tablet	36501266
	nirmatrelvir and ritonavir KIT	36900648
	nirmatrelvir and ritonavir KIT	42631714
	nirmatrelvir and ritonavir KIT [paxlovid]	1632579
	nirmatrelvir and ritonavir KIT [paxlovid]	749191
	nirmatrelvir and ritonavir KIT [paxlovid]	36901848
	ritonavir 100 MG Oral Tablet	36501120
	{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]	42631191
	{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]	1626323
	{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]	36900156
	{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]	1994869
	Paxlovid - Ruvos	nirmatrelvir
nirmatrelvir 150 MG		702531
nirmatrelvir 150 MG Oral Tablet		702535
nirmatrelvir Oral Product		702532
nirmatrelvir Oral Tablet		702534
nirmatrelvir Pill		702533
{10 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack		780185
{10 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 150 MG /100 MG Dose Pack]		780186
{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack		702577
{20 (nirmatrelvir 150 MG Oral Tablet) / 10 (ritonavir 100 MG Oral Tablet) } Pack [Paxlovid 5-Day]		702578

eTable 2. Complete Baseline Characteristics of the Paxlovid-treated and Untreated No Paxlovid Groups Prior to Weighting

Characteristic	No Paxlovid, N = 914850[†]	Paxlovid, N = 98060[†]
Hospitalized	8285 (0.9%)	652 (0.7%)
Death	1480 (0.2%)	35 (<0.1%)
Number of visits before COVID-19	34 (14, 69)	54 (25, 98)
Age	48 (34, 63)	58 (44, 69)
Male	329932 (36%)	35345 (36%)
Female	584918 (64%)	62715 (64%)
BMI		
MISSING BMI	321569 (35%)	9620 (9.8%)
NORMAL	72581 (7.9%)	11211 (11%)
OBESE	243191 (27%)	36599 (37%)
OBESE CLASS 3	96548 (11%)	15132 (15%)
OVERWEIGHT	173223 (19%)	24972 (25%)
UNDERWEIGHT	7738 (0.8%)	526 (0.5%)
White	620468 (68%)	71134 (73%)
Black	132743 (15%)	11191 (11%)
Hispanic	80431 (8.8%)	7737 (7.9%)
Asian	20235 (2.2%)	2655 (2.7%)
Native American	4287 (0.5%)	373 (0.4%)
Native Hawaiian/ Pacific Islander	924 (0.1%)	91 (<0.1%)
Other or Unknown	59622 (6.5%)	4879 (4.9%)
COVID Vaccine Doses		
0	548225 (60%)	39570 (40%)
1	50533 (5.5%)	5497 (5.6%)
2	159855 (17%)	14949 (15%)
3	131435 (14%)	25089 (26%)
4	24802 (2.7%)	12955 (13%)
Rifampin	1330 (0.1%)	253 (0.3%)
Tolvaptan	67 (<0.1%)	<20 (<0.1%)
Carbamazepine	2351 (0.3%)	276 (0.3%)
Sildenafil	15920 (1.7%)	3655 (3.7%)
Quinidine	146 (<0.1%)	<20 (<0.1%)
Salmeterol	18896 (2.1%)	3325 (3.4%)
Pimozide	37 (<0.1%)	<20 (<0.1%)
Sildenafil	526 (<0.1%)	91 (<0.1%)
Lurasidone	2884 (0.3%)	217 (0.2%)
Phenobarbital	1469 (0.2%)	149 (0.2%)
Primidone	1329 (0.1%)	149 (0.2%)
Triazolam	1328 (0.1%)	136 (0.1%)
Phenytoin	1069 (0.1%)	58 (<0.1%)
Ergotamine	106 (<0.1%)	<20 (<0.1%)
Rivaroxaban	9712 (1.1%)	1016 (1.0%)
Flibanserin	101 (<0.1%)	<20 (<0.1%)
Ivacaftor Lumacaftor	120 (<0.1%)	25 (<0.1%)
Ubrogepant	1155 (0.1%)	200 (0.2%)
Lomitapide	<20 (<0.1%)	<20 (<0.1%)
Eletriptan	1747 (0.2%)	286 (0.3%)
Finerenone	<20 (<0.1%)	<20 (<0.1%)
Dronedarone	500 (<0.1%)	48 (<0.1%)

Dihydroergotamine	392 (<0.1%)	47 (<0.1%)
Voclosporin	<20 (<0.1%)	<20 (<0.1%)
Alfuzosin	1923 (0.2%)	371 (0.4%)
Amiodarone	5065 (0.6%)	471 (0.5%)
Colchicine	7378 (0.8%)	1323 (1.3%)
Midazolam	132858 (15%)	21752 (22%)
Propafenone	555 (<0.1%)	40 (<0.1%)
Ranolazine	1404 (0.2%)	98 (<0.1%)
Eplerenone	485 (<0.1%)	61 (<0.1%)
Cvdt Flecainide	2020 (0.2%)	200 (0.2%)
Naloxegol	805 (<0.1%)	215 (0.2%)
Down Syndrome	176 (<0.1%)	20 (<0.1%)
Cerebral Palsy	1963 (0.2%)	221 (0.2%)
Developmental Disorder	98432 (11%)	11821 (12%)
Spinal Cord Injury	167 (<0.1%)	<20 (<0.1%)
Hemiplegia or Paraplegia	6925 (0.8%)	652 (0.7%)
Autism	3589 (0.4%)	376 (0.4%)
ADHD	37504 (4.1%)	4085 (4.2%)
Anxiety	312515 (34%)	37901 (39%)
Psychosis	12393 (1.4%)	786 (0.8%)
Mood Disorder	243695 (27%)	29059 (30%)
Depression	224967 (25%)	27211 (28%)
Schizophrenia Spectrum Psychotic Disorders	14074 (1.5%)	901 (0.9%)
Mental Disorder	380425 (42%)	46411 (47%)
Mental Health Disorder	11097 (1.2%)	672 (0.7%)
Chronic Lung Disease	192005 (21%)	25339 (26%)
Tuberculosis	1216 (0.1%)	128 (0.1%)
Asthma	139961 (15%)	19322 (20%)
Cystic Fibrosis	616 (<0.1%)	73 (<0.1%)
Tobacco Smoker	65619 (7.2%)	6897 (7.0%)
Substance Use Disorder	159034 (17%)	13128 (13%)
Current smoker	77043 (8.4%)	7526 (7.7%)
Atrial Fibrillation	41908 (4.6%)	3886 (4.0%)
Atrial Arrhythmias	40426 (4.4%)	3715 (3.8%)
Cardiomyopathies	20156 (2.2%)	2258 (2.3%)
Hypertension	342282 (37%)	46750 (48%)
CAD	73144 (8.0%)	9498 (9.7%)
CHF	25162 (2.8%)	2482 (2.5%)
Myocardial Infarction	24353 (2.7%)	2859 (2.9%)
Peripheral Vascular Disease	30113 (3.3%)	3703 (3.8%)
Thalassemia	1103 (0.1%)	135 (0.1%)
Sickle Cell Disease	974 (0.1%)	103 (0.1%)
Acute Myocarditis	157 (<0.1%)	<20 (<0.1%)
Heart Failure	34026 (3.7%)	3374 (3.4%)
Atherosclerosis	81107 (8.9%)	10632 (11%)
CerebroVascular disease	56547 (6.2%)	7531 (7.7%)
Ischemic Stroke	22115 (2.4%)	2441 (2.5%)
Autoimmune Disease Immunodeficiency	81230 (8.9%)	11807 (12%)
Immunosuppressive Therapies	61434 (6.7%)	10565 (11%)
Rheumatologic Disease	59928 (6.6%)	9259 (9.4%)
Multisystem inflammatory syndrome	48 (<0.1%)	<20 (<0.1%)
Hematologic Cancer	15469 (1.7%)	2236 (2.3%)

Basal Cell Carcinoma	12439 (1.4%)	2730 (2.8%)
Metastatic Solid Tumor Cancers	8893 (1.0%)	1255 (1.3%)
Cancer	81853 (8.9%)	12969 (13%)
Mild Liver Disease	57096 (6.2%)	7703 (7.9%)
Diabetes Complicated	64985 (7.1%)	8988 (9.2%)
CKG	21741 (2.4%)	2212 (2.3%)
CKD	30633 (3.3%)	3280 (3.3%)
Diabetes Uncomplicated	155424 (17%)	20143 (21%)
Moderate to Severe Liver Disease	4517 (0.5%)	425 (0.4%)
Pregnant	75121 (8.2%)	4546 (4.6%)
HIV	5849 (0.6%)	934 (1.0%)
Dementia	18590 (2.0%)	1935 (2.0%)
Charlson Comorbidity Index (Median (IQR))	1 (0, 2)	1 (0, 2)
Transplant	12176 (1.3%)	931 (0.9%)
Systemic Corticosteroids	370395 (40%)	50299 (51%)
Peptic ulcer	12653 (1.4%)	1820 (1.9%)
African American (%)	0.06 (0.02, 0.16)	0.07 (0.02, 0.17)
Asian (%)	0.02 (0.01, 0.06)	0.03 (0.01, 0.07)
Hispanic (%)	0.07 (0.03, 0.13)	0.08 (0.05, 0.15)
Poverty Status (%)	0.11 (0.07, 0.17)	0.10 (0.06, 0.16)
Unemployed (Age 20 to 64)	0.041 (0.030, 0.056)	0.039 (0.030, 0.049)
Bachelors Highest Degree (%)	0.20 (0.14, 0.27)	0.24 (0.17, 0.30)
Graduate Professional Degree (%)	0.11 (0.07, 0.18)	0.14 (0.09, 0.23)
¹ Statistics presented: n (%); median (IQR)		

eTable 3. Ratio of Probability of Hospitalization and Death in Paxlovid-Treated versus Untreated Patients from Weighted Cause Specific Hazard Model and QuasiPoisson Regression Analyses

Analysis	Technique	Outcome	Risk Ratio (95% CI)
Main	Competing Risk ¹	Hospitalization	0.742 (0.689 to 0.812)
	Quasipoisson ²	Hospitalization	0.742 (0.679 to 0.811)
	Quasipoisson	Mortality	0.269 (0.189 to 0.381)
	KaplanMeier ³	Mortality	0.269 (0.179 to 0.37)
Sensitivity: Remove SDoH	Competing Risk	Hospitalization	0.739 (0.689 to 0.808)
	QuasiPoisson	Hospitalization	0.739 (0.68 to 0.803)
	QuasiPoisson	Mortality	0.282 (0.209 to 0.383)
	KaplanMeier	Mortality	0.284 (0.201 to 0.394)
Sensitivity: Exclude death within 3 Days	Competing Risk	Hospitalization	0.743 (0.687 to 0.809)
	QuasiPoisson	Hospitalization	0.743 (0.68 to 0.812)
	QuasiPoisson	Mortality	0.297 (0.208 to 0.425)
	KaplanMeier	Mortality	0.292 (0.193 to 0.392)
Sensitivity: Drop mild COVID eligibility	Competing Risk	Hospitalization	0.682 (0.634 to 0.738)
	QuasiPoisson	Hospitalization	0.682 (0.632 to 0.735)
	QuasiPoisson	Mortality	0.187 (0.142 to 0.248)
	KaplanMeier	Mortality	0.186 (0.142 to 0.241)
Sensitivity: Include age >= 50 as risk factor	Competing Risk	Hospitalization	0.716 (0.663 to 0.784)
	QuasiPoisson	Hospitalization	0.715 (0.656 to 0.78)
	QuasiPoisson	Mortality	0.248 (0.177 to 0.347)
	KaplanMeier	Mortality	0.245 (0.182 to 0.319)
Sensitivity: Include age >= 65 as risk factor	Competing Risk	Hospitalization	0.727 (0.667 to 0.798)
	QuasiPoisson	Hospitalization	0.727 (0.667 to 0.794)
	QuasiPoisson	Mortality	0.249 (0.178 to 0.349)
	KaplanMeier	Mortality	0.249 (0.179 to 0.344)
Sensitivity: Paxlovid treatment within 2 days from index	Competing Risk	Hospitalization	0.735 (0.666 to 0.786)
	QuasiPoisson	Hospitalization	0.735 (0.673 to 0.804)
	QuasiPoisson	Mortality	0.271 (0.191 to 0.384)
	KaplanMeier	Mortality	0.270 (0.173 to 0.365)
Sensitivity: Exclude missing BMI	Competing Risk	Hospitalization	0.716 (0.654 to 0.774)
	QuasiPoisson	Hospitalization	0.715 (0.656 to 0.78)
	QuasiPoisson	Mortality	0.248 (0.177 to 0.347)
	KaplanMeier	Mortality	0.243 (0.165 to 0.32)
Sensitivity: 90D lookback for exclusion criteria	Competing Risk	Hospitalization	0.743 (0.688 to 0.819)
	QuasiPoisson	Hospitalization	0.743 (0.68 to 0.812)
	QuasiPoisson	Mortality	0.269 (0.189 to 0.381)
	KaplanMeier	Mortality	0.267 (0.182 to 0.379)

Notes.



¹ Risk ratios were derived from weighted cause-specific hazard models accounting for competing risk of death, which were used to estimate cumulative incidence functions for treated and untreated patients. The risk ratio estimate was obtained as the average difference in absolute risk of hospitalization at 28 days across 100 bootstraps. 95% CIs were obtained by taking the 2.5th and 97.5th percentile values of the risk differences across the 100 bootstraps.

² Risk ratios and 95% CIs were derived from weighted quasipoisson regression treating hospitalization or death at 28 days as the outcome.


³ Risk ratios were derived from weighted kaplan-meier cumulative incidence curves for treated and untreated patients. The risk ratio estimate was obtained as the average difference in absolute risk of death at 28 days across 100 bootstraps. 95% CIs were obtained by taking the 2.5th and 97.5th percentile values of the risk differences across the 100 bootstraps.

eTable 4: Proportion of Eligible patients treated across study period in Hawaii and Alaska.


State	Proportion Treated Between Dec. 2021 and Feb. 2023
Hawaii	0.047
Alaska	0.086




eFigure 1. Love plot and balance plots that show the balance of covariates before and after running the IPTW model and computing weights.




Paxlovid Eligible




eFigure 2: Counts of total eligible patients per 2-digit zip code across the entire study period.



eFigure 3. Distribution of log total treated patients by number of days from COVID-19 diagnosis date.



eFigure 4. Distribution of total treated patients by number of days from COVID-19 diagnosis date.



eFigure 5. Projections of the percent reduction in hospitalizations (top) and deaths (bottom) at varying degrees of Paxlovid uptake at eligibility proportions of 30, 50 and 70 percent, applying the estimated relative risk of hospitalization and death for Paxlovid-treated versus untreated obtained in the main outcome analyses.